DelveInsight’s, “Oligodendroglioma Pipeline Insight, 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Oligodendroglioma pipeline landscape. It covers the Oligodendroglioma pipeline drug profiles, including Oligodendroglioma clinical trials and nonclinical stage products. It also covers the Oligodendroglioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Oligodendroglioma emerging drugs, the Oligodendroglioma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Oligodendroglioma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Oligodendroglioma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Oligodendroglioma clinical trials studies, Oligodendroglioma NDA approvals (if any), and product development activities comprising the technology, Oligodendroglioma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Oligodendroglioma Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Oligodendroglioma Pipeline landscape @ Oligodendroglioma Pipeline Outlook Report
Oligodendroglioma Overview
Oligodendroglioma (OG) is a type of diffusely infiltrating glioma and constitutes approximately 5% of primary intracranial tumors. Oligodendroglial tumors can be divided into two groups based on the classification of the world health organization (WHO): grade II oligodendroglioma and grade III (anaplastic) oligodendroglioma. Most commonly occurring between 25 and 45 years of age, grade III oligodendrogliomas tend to present 10 years later than grade II tumors and can rarely develop in younger and older populations. Oligodendroglioma is genetically defined as a tumor confirmed to harbor either an IDH1 or IDH2 mutation along with co-deletion of chromosome arms 1p and 19q.
Latest Developmental Activities in the Oligodendroglioma Treatment Landscape
For further information, refer to the detailed Oligodendroglioma Unmet Needs, Oligodendroglioma Market Drivers, and Oligodendroglioma Market Barriers, click here for Oligodendroglioma Ongoing Clinical Trial Analysis
Oligodendroglioma Emerging Drugs Profile
ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist in late-stage clinical development for recurrent gliomas that harbor the H3 K27M mutation. Recurrent glioma is a form of brain cancer with a particularly poor prognosis having a median overall survival of approximately eight months. Recurrent pediatric patients, with cancer that carries the H3 K27M mutation, have an even worse prognosis with median overall survival of approximately four months. Compelling responses at this stage of disease are rare and lack durability. Patients with this mutation are considered grade IV by the World Health Organization, regardless of underlying histology or age.
RRx-001 is a lead small molecule, immunotherapy targeting the CD47 – SIRPα axis and has been evaluated in multiple clinical studies. The genesis for the PIRATE trial was based on several preceding clinical trials which have established potential evidence that RRx-001 increases chemotherapy delivery and uptake in tumors. A Phase 1 clinical trial called G-FORCE (NCT02871843) and a Phase 1/2 clinical trial called BRAINSTORM (NCT02215512) demonstrated the safety of RRx-001 as well as potential evidence of clinical benefit in adult patients with glioblastoma or GBM and with brain metastases, respectively.
Oligodendroglioma Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies Oligodendroglioma. The companies which have their Oligodendroglioma drug candidates in the most advanced stage, i.e. Phase II include, Pfizer.
Request a sample and discover the recent advances in Oligodendroglioma Ongoing Clinical Trial Analysis and Medications, click here @ Oligodendroglioma Treatment Landscape
Scope of the Oligodendroglioma Pipeline Report
Dive deep into rich insights for drugs for Oligodendroglioma Market Drivers and Oligodendroglioma Market Barriers, click here @ Oligodendroglioma Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Oligodendroglioma Mergers and acquisitions, Oligodendroglioma Licensing Activities @ Oligodendroglioma Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services